Grufity logoGrufity logo

GH

51.10USD-0.42(-0.82%)Market Closed

Guardant Health, Inc.

Market Summary

USD51.10-0.42Market Closed
-0.82%

GH Alerts

GH Stock Price

RSI Chart

Valuation

Market Cap

4.9B

Price/Earnings

-9.19

Price/Sales

11.99

Price/Cashflow

-18.07

MarketCap/EBT

-9.2

Price/Sales

Profitability

EBT Margin

-130.34%

Return on Equity

-166.88%

Return on Assets

-28.73%

Fundamentals

Revenue

Revenue (TTM)

408.1M

Revenue Y/Y

18.5%

Revenue Q/Q

13.57%

Earnings

Earnings (TTM)

-532.5M

Earnings Y/Y

-135.13%

Earnings Q/Q

-86.18%

Price Action

52 Week Range

27.65108.50
(Low)(High)

Last 7 days

6.1%

Last 30 days

6.8%

Last 90 days

6.0%

Trailing 12 Months

-52.2%

Financial Health

Current Ratio

6.18

Investor Care

Shares Dilution (1Y)

0.91%

Diluted EPS (TTM)

-5.41

Peers (Alternatives to Guardant Health)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
64.2B
59.8B
4.78% 2.18%
9.86
1.07
3.14% -18.15%
20.3B
15.3B
6.59% -16.89%
10.19
1.29
-7.83% -36.44%
16.9B
10.3B
3.10% -1.90%
13.7
1.64
-6.81% -43.45%
MID-CAP
8.6B
13.2B
10.35% 4.15%
11.12
0.66
6.21% -30.27%
5.5B
5.5B
-2.89% 5.56%
11.91
1.05
68.51% 117.01%
5.5B
5.1B
2.80% 16.95%
16.63
1.03
1.10% -32.81%
5.2B
2.3B
0.78% 35.72%
54.18
2.25
7.63% -28.34%
5.0B
2.9B
3.06% 19.32%
23.43
1.72
13.49% 10.78%
4.9B
408.1M
6.77% -52.21%
-9.19
11.99
26.10% -44.06%
3.2B
2.2B
-7.60% -39.91%
26.22
1.43
0.68% -45.06%
SMALL-CAP
1.1B
1.4B
-7.73% -34.23%
47.05
0.81
6.94% -77.50%
849.9M
2.8B
-35.60% -53.71%
-9.25
0.32
-6.67% -377.23%
105.7M
111.6M
-11.06% -42.90%
-16.12
0.95
-0.75% -611.70%
41.6M
46.8M
13.28% -73.68%
-1.1
0.94
-3.12% -66.57%
36.2M
26.0M
-9.33% -29.94%
-30.63
1.38
9.09% -588.38%

Financials for Guardant Health

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue4.4%408391374344324
  S&GA Expenses11.7%248222192164138
  R&D Expenses7.5%311289263230196
Earnings Before Taxes-32.8%-531.97-400.47-384.47-404.95-369.12
Net Income-32.9%-532.50-400.64-384.77-405.50-369.65
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-13.0%1,8542,1302,2042,2262,292
  Current Assets-6.8%1,0371,1131,1141,5931,891
    Cash Equivalents-62.5%215574492832939
  Inventory63.6%6037312526
  Net PPE8.0%16315112410690
  Goodwill0%33333
Liabilities-3.9%1,5351,5971,5591,4571,444
  Current Liabilities-26.7%16822919510297
Shareholder's Equity-40.1%319533645709788
  Retained Earnings-20.3%-1,360.48-1,131.05-1,007.82-916.91-809.39
  Additional Paid-In Capital1.3%1,7041,6821,6581,6271,597
Accumulated Depreciation13.1%7061554944
Shares Outstanding0.3%102102102102101
Float-12,100----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-22.3%-270.69-221.34-209.02-191.25-146.16
  Share Based Compensation-7.4%112121151181202
Cashflow From Investing-262.4%-276.18-76.22-63.15-94.14-61.40
Cashflow From Financing-5678.4%-173.883-66.82976982

Risks

What is the probability of a big loss on GH?

95.0%


Probability that Guardant Health stock will be more than 20% underwater in next one year

81.3%


Probability that Guardant Health stock will be more than 30% underwater in next one year.

51.1%


Probability that Guardant Health stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Guardant Health was unfortunately bought at previous high price.

Returns

Cumulative Returns on GH

-13.0%


3-Year Cumulative Returns

Which funds bought or sold GH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
FourThought Financial, LLC
-
-
-296,000
7,000
-%
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
2,757,000
2,757,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
1,485,000
6,333,000
0.01%
2022-11-17
CENTRAL TRUST Co
SOLD OFF
-100
-1,000
-
-%
2022-11-17
M&T Bank Corp
NEW
-
202,000
202,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-44,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
SeaCrest Wealth Management, LLC
SOLD OFF
-100
-48,000
-
-%
2022-11-15
CIBC Private Wealth Group, LLC
SOLD OFF
-100
-
-
-%
2022-11-15
Railway Pension Investments Ltd
UNCHANGED
-
5,114,000
20,406,000
0.22%

1–10 of 38

Latest Funds Activity

Are funds buying GH calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own GH

Guardant Health News

Yahoo Entertainment

Now is the time to buy an Echo Dot smart speaker on Amazon — prices start at just $14.99, and the newest model is under $40!.7 hours ago

GH Fair Value

Recent SEC filings of Guardant Health

View All Filings
Date Filed Form Type Document
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 09, 2022
4
Insider Trading
Nov 09, 2022
4
Insider Trading
Nov 09, 2022
4
Insider Trading
Nov 09, 2022
4
Insider Trading
Nov 09, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 03, 2022
10-Q
Quarterly Report
Nov 03, 2022
8-K
Current Report

Latest Insider Trading transactions for GH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-15
POTTER MYRTLE S
ACQUIRED
-
-
69
-
2022-11-15
Kalia Kumud
SOLD
-162,082
51.8663
-3,125
Chief Information Officer
2022-11-04
Joyce Meghan V.
ACQUIRED
-
-
67
-
2022-10-15
POTTER MYRTLE S
ACQUIRED
-
-
820
-
2022-09-09
Merrill Amelia
SOLD (Taxes)
-21,518.6
59.28
-363
SVP, People
2022-09-09
Kalia Kumud
ACQUIRED
-
-
6,544
Chief Information Officer
2022-09-09
Kalia Kumud
SOLD (Taxes)
-192,364
59.28
-3,245
Chief Information Officer
2022-09-09
Saia John G.
SOLD (Taxes)
-17,902.6
59.28
-302
See Remarks
2022-09-09
Merrill Amelia
ACQUIRED
-
-
1,047
SVP, People
2022-09-04
Joyce Meghan V.
ACQUIRED
-
-
66
-

1–10 of 50

Helmy Eltoukhy
1370
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

GH Income Statement

2022-09-30
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Precision oncology testing$ 102,054$ 79,272$ 278,252$ 215,605
Development services and other15,35015,50744,39549,940
Total revenue117,40494,779322,647265,545
Costs and operating expenses:    
Cost of precision oncology testing39,43429,665104,49378,142
Cost of development services and other1,0621,1514,71111,348
Research and development expense100,01770,968267,229190,200
Sales and marketing expense80,37050,228218,405132,282
General and administrative expense41,12150,055126,068166,366
Total costs and operating expenses262,004202,067720,906578,338
Loss from operations(144,600)(107,288)(398,259)(312,793)
Interest income1,7546893,9193,277
Interest expense(644)(644)(1,933)(1,934)
Other income (expense), net(18,389)(187)(18,059)(720)
Fair value adjustments of noncontrolling interest liability00(99,785)0
Loss before provision for income taxes(161,879)(107,430)(514,117)(312,170)
Provision for income taxes11596537289
Net loss(161,994)(107,526)(514,654)(312,459)
Adjustment of redeemable noncontrolling interest000(2,300)
Net loss attributable to Guardant Health, Inc. common stockholders(161,994)(107,526)(514,654)(314,759)
Net loss attributable to Guardant Health, Inc. common stockholders$ (161,994)$ (107,526)$ (514,654)$ (314,759)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)$ (1.58)$ (1.06)$ (5.04)$ (3.11)
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)$ (1.58)$ (1.06)$ (5.04)$ (3.11)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)102,289101,420102,065101,184
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)102,289101,420102,065101,184

GH Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 158,310$ 492,202
Short-term marketable debt securities799,727440,546
Accounts receivable, net86,20097,652
Inventory, net63,04730,674
Prepaid expenses and other current assets, net23,56553,052
Total current assets1,130,8491,114,126
Long-term marketable debt securities156,741698,034
Property and equipment, net168,007124,461
Right-of-use assets, net178,747189,443
Intangible assets, net12,41714,207
Goodwill3,2903,290
Other assets, net51,72860,938
Total Assets[1]1,701,7792,204,499
Current liabilities:  
Accounts payable40,91117,580
Accrued compensation57,42342,496
Accrued expenses63,36745,285
Noncontrolling interest liability078,000
Deferred revenue13,42311,326
Total current liabilities175,124194,687
Convertible senior notes, net1,136,7481,134,821
Long-term operating lease liabilities216,174226,053
Other long-term liabilities6,9883,933
Total Liabilities[1]1,535,0341,559,494
Stockholders’ equity:  
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2022 and December 31, 202100
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of September 30, 2022, and December 31, 2021; 102,413,638 and 101,767,446 shares issued and outstanding as of September 30, 2022, and December 31, 2021, respectively11
Additional paid-in capital1,716,0751,657,593
Accumulated other comprehensive loss(26,852)(4,764)
Accumulated deficit(1,522,479)(1,007,825)
Total Stockholders’ Equity166,745645,005
Total Liabilities and Stockholders’ Equity$ 1,701,779$ 2,204,499
[1]As of December 31, 2021, the Company's consolidated balance sheet included $20.4 million of assets, that can be used only to settle obligations of Guardant Health AMEA, Inc., the consolidated variable interest entity, or VIE, and VIE’s subsidiaries, and $4.3 million of liabilities of the consolidated VIE and VIE’s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. Guardant Health AMEA, Inc. is no longer a VIE, after the completion of the Joint Venture Acquisition on June 10, 2022. See Note 3,